In RCC, EGR2 promotes the expression of IGF2BPs, enhancing the stability of S1PR3 mRNA, ultimately affecting the PI3K/AKT pathway, and promoting RCC tumorigenesis [127]. Here, S1PR3 is linked to renal cell carcinoma.